{"title":"用于DOAC逆转的新药物:一项实用的管理综述。","authors":"Katie White, Uzma Faruqi, Alexander Ander T Cohen","doi":"10.5837/bjc.2022.001","DOIUrl":null,"url":null,"abstract":"<p><p>Bleeding is the commonest and most concerning adverse event associated with anticoagulants. Bleeding, depending on the severity, is managed in various ways, and for severe or life-threatening bleeding, specific antidotes are indicated and recommended. This review provides guidance relating to specific direct oral anticoagulant (DOAC) reversal agents, the antidotes. We discuss their indications for use, dosing, and potential side effects.</p>","PeriodicalId":74959,"journal":{"name":"The British journal of cardiology","volume":"29 1","pages":"1"},"PeriodicalIF":0.0000,"publicationDate":"2022-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196076/pdf/BJC-29-01-bjc.2022.001.pdf","citationCount":"9","resultStr":"{\"title\":\"New agents for DOAC reversal: a practical management review.\",\"authors\":\"Katie White, Uzma Faruqi, Alexander Ander T Cohen\",\"doi\":\"10.5837/bjc.2022.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Bleeding is the commonest and most concerning adverse event associated with anticoagulants. Bleeding, depending on the severity, is managed in various ways, and for severe or life-threatening bleeding, specific antidotes are indicated and recommended. This review provides guidance relating to specific direct oral anticoagulant (DOAC) reversal agents, the antidotes. We discuss their indications for use, dosing, and potential side effects.</p>\",\"PeriodicalId\":74959,\"journal\":{\"name\":\"The British journal of cardiology\",\"volume\":\"29 1\",\"pages\":\"1\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-01-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196076/pdf/BJC-29-01-bjc.2022.001.pdf\",\"citationCount\":\"9\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The British journal of cardiology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5837/bjc.2022.001\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The British journal of cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5837/bjc.2022.001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
New agents for DOAC reversal: a practical management review.
Bleeding is the commonest and most concerning adverse event associated with anticoagulants. Bleeding, depending on the severity, is managed in various ways, and for severe or life-threatening bleeding, specific antidotes are indicated and recommended. This review provides guidance relating to specific direct oral anticoagulant (DOAC) reversal agents, the antidotes. We discuss their indications for use, dosing, and potential side effects.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
